Investor Relations

Webcast ImageWebcast
Navidea Biopharmaceuticals Inc at 2016 Aegis Growth Conference (Replay)
09/22/16 at 9:30 a.m. PT
Navidea Biopharmaceuticals Inc at 2016 Aegis Growth Conference
Thursday, September 22, 2016 9:30 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Navidea Biopharmaceuticals Inc at Ladenburg Thalmann 2016 Healthcare Conference (Replay)
09/27/16 at 4:00 p.m. ET
Navidea Biopharmaceuticals Inc at Ladenburg Thalmann 2016 Healthcare Conference
Tuesday, September 27, 2016 4:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Navidea Biopharmaceuticals is a commercial stage biotechnology company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing the precision-targeted Manocept™ platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Today's Quote

NAVB (Common Stock)
ExchangeNYSE Amex (US Dollar)
Price$0.91
Change (%) Stock is Up 0.01 (2.25%)
Volume1,130,502
Data as of 09/27/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.